The Office of Research is pleased to announce two funding opportunities: 1.) A Request for Proposals (RFP) has been issued for a new Office of Research funded Centers of Excellence. A Letter of Intent (LOI) must be submitted no later than 11/1/24. Go HERE for the RFP and LOI details. 2.) Office of Research Bridge Fund Award applications will be accepted until 12/1/24. Go HERE for more information.

Daidzein analogs for the treatment and prevention of cancer

Background

Tulane University is actively seeking commercial entities to further develop and commercialize daidzein analogs to treat or prevent cancer and tumor growth.

Applications

Daidzein analogs may be used as a selective estrogen receptor modulator (SERM) therapeutic for estrogen receptor-positive breast cancer. Analogs may be used as a novel anti-metastatic therapeutic in triple negative breast carcinoma. Daidzein analogs do not increase the risk of uterine cancer or blood clots unlike Tamoxifen, a common SERM on the market. Analogs are suitable for oral administration in solid or liquid form and may also be delivered via parenteral administration. Daidzein analogs have applicability to a range of cancer types, particularly to hormone-responsive cancers.

Current Work

This technology has been tested extensively in the lab and in mice with success using various tumor types and treatment modalities.

Inventors

Intellectual Property

Available For

Exclusive License in a Field
Non-exclusive License
Scientific Collaboration

For more information, please contact: